Pharmaceutical composition, preparation and uses thereof

Abstract

The invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle, said biocompatible nanoparticle comprising at least one oligomer of albumin (n≧2) or consisting in an oligomer of albumin, and of (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least one nanoparticle potentiates the at least one compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm. The invention also relates to such a composition for use for administering the at least one compound of interest in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one compound of interest are to be administered in said subject sequentially, typically between more than 5 minutes and about 72 hours one from each other.

1 - 9 . (canceled) 
     
     
         10 . A therapeutic, prophylactic or diagnostic method comprising a step of administering at least one pharmaceutical compound to a subject in need thereof and a distinct step of administering at least one biocompatible nanoparticle to said subject, wherein the at least one pharmaceutical compound comprises at least one antibody; the at least one biocompatible nanoparticle comprises at least one oligomer of albumin (n≧2), the longest or largest dimension of the at least one biocompatible nanoparticle is between about 4 nm and about 500 nm, the at least one biocompatible nanoparticle is not used as a pharmaceutical compound and said at least one nanoparticle is administered to the subject between 5 minutes and about 72 hours after the pharmaceutical compound. 
     
     
         11 . The method according to  claim 10 , wherein the at least one oligomer of albumin is a dimer of albumin (n=2), a trimer of albumin (n=3), or comprises at least 4 monomers of albumin (n=4). 
     
     
         12 . The method according to  claim 10 , wherein the at least one oligomer of albumin comprises less than 50 monomers of albumin or less than 25 monomers of albumin. 
     
     
         13 . The method according to  claim 10 , wherein albumin monomers are conjugated to each other to form an albumin oligomer through direct interaction or via a linker. 
     
     
         14 . The method according to  claim 13 , wherein the linker is a crosslinker comprising at least one maleimide group. 
     
     
         15 . The method according to  claim 13 , wherein distinct biocompatible nanoparticles comprising at least one oligomer of albumin (n≧2) are administered to the subject. 
     
     
         16 . The method according to  claim 10 , wherein the pharmaceutical compound comprises at least one antibody and said at least one antibody is selected from a monoclonal antibody, a drug conjugated antibody, an engineered antibody and a multispecific antibody. 
     
     
         17 . The method according to  claim 10 , wherein the administration of the at least one biocompatible nanoparticle and of the pharmaceutical compound maintains or increases the therapeutic benefit of the pharmaceutical compound and reduces toxicity, when compared to therapeutic benefit and toxicity induced by the standard therapeutic dose of said pharmaceutical compound in the absence of biocompatible nanoparticle.